Imunon, Inc.IMNNEarnings & Financial Report
Imunon, Inc. is a clinical-stage biotechnology company specializing in the development of innovative immunotherapies and nucleic acid-based therapeutics. Its core product candidates target multiple solid tumor types and infectious diseases, serving global patient populations through partnerships with healthcare and research institutions across North America, Europe and the Asia-Pacific.
IMNN Q4 FY2022 Key Financial Metrics
Revenue
$125.0K
Gross Profit
N/A
Operating Profit
$-6.9M
Net Profit
$-13.2M
Gross Margin
N/A
Operating Margin
-5541.4%
Net Margin
-10586.1%
YoY Growth
0.0%
EPS
$-1.47
Imunon, Inc. Q4 FY2022 Financial Summary
Imunon, Inc. reported revenue of $125.0K (up 0.0% YoY) for Q4 FY2022, with a net profit of $-13.2M (down 213.5% YoY) (-10586.1% margin).
Key Financial Metrics
| Total Revenue | $125.0K |
|---|---|
| Net Profit | $-13.2M |
| Gross Margin | N/A |
| Operating Margin | -5541.4% |
| Report Period | Q4 FY2022 |
Imunon, Inc. Annual Revenue by Year
Imunon, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $500.0K).
Imunon, Inc. Quarterly Revenue & Net Profit History
Imunon, Inc. results over the last 4 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2022 | $125.0K | +0.0% | $-13.2M | -10586.1% |
| Q3 FY2022 | $125.0K | +0.0% | $-6.1M | -4918.6% |
| Q2 FY2022 | $125.0K | +0.0% | $-6.0M | -4834.3% |
| Q1 FY2022 | $125.0K | +0.0% | $-10.5M | -8379.5% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Revenue | $125000 | $125000 | $125000 | $125000 |
| YoY Growth | 0.0% | 0.0% | 0.0% | 0.0% |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Assets | $64.3M | $65.3M | $60.5M | $44.0M |
| Liabilities | $18.1M | $18.3M | $19.2M | $14.6M |
| Equity | $46.3M | $47.0M | $41.4M | $29.3M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | |
|---|---|---|---|---|
| Operating CF | $-8.0M | $-5.5M | $-4.6M | $-5.0M |